US Oncology Research Announces Schedule of Presentations at the 2014 American Society of Hematology Annual Meeting and Exposition

December 03, 2014

Leading investigators affiliated with US Oncology Research and The US Oncology Network involved in 20 oral presentations, including a “Best of ASH” on chronic lymphocytic leukemia

The Woodlands, Texas (December 3, 2014) — More than 13 leading investigators affiliated with US Oncology Research and The US Oncology Network, both supported by McKesson Specialty Health, participated in twenty studies that will be presented at the 56th American Society of Hematology (ASH) Annual Meeting and Exposition at the Moscone Center in San Francisco, CA. ASH will be held Dec. 6-9, and is the premier scientific event in malignant and non-malignant hematology. Three oral and 17 poster presentations will be made by investigators affiliated with US Oncology Research, with clinical data on chronic lymphocytic leukemia (CLL), chronic myeloid leukemia and Hodgkin’s lymphoma being featured, among other clinical findings.

Jeffrey P. Sharman, M.D., director of research at Willamette Valley Cancer Institute and medical director of hematology research for The US Oncology Network, will discuss the results of a study titled “Second Interim Analysis of a Phase 3 Study of Idelalisib (ZYDELIG®) Plus Rituximab® for Relapsed Chronic Lymphocytic Leukemia: Efficacy Analysis in Patient Subpopulations with Del(p) and Other Adverse Prognostic Factors.” The study has been selected as a “Best of ASH” oral presentation, and will be presented on Monday, December 8, 2014: 8:15 AM in the West Building (3001-3003-3014-3016) of the Moscone Center.

“It’s exciting to see new research on blood disorders such as lymphoma and chronic lymphocytic leukemia,” said Dr. Sharman. “We are witnessing a time of unprecedented breakthroughs as better understanding of cancer biology is being translated into therapies that are both more effective and often have fewer side effects.”

Dr. Sharman and Dr. Christopher Yasenchak also with Willamette Valley Cancer Institute are also the co-author of a trial titled “Brentuximab Vedotin Monotherapy and in Combination with Dacarbazine in Frontline Treatment of Hodgkin Lymphoma in Patients Aged 10 Years and Above: Interim Results of a Phase ll Study.” Results of the trial will be featured as an oral presentation on Monday, December 8, 2014: 7:00 AM-8:30 AM in the Moscone Center West Building (3009-3011-3022-3024)

Additionally, David Andorsky, M.D., medical oncologist with Rocky Mountain Cancer Centers, co-authored a trial titled, “Epic: A Phase 3 Trial of Ponatinib Compared with Imatinib in Patients with Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CP-CML).” The oral presentation of this trial will occur on Monday, December 8, 2014: 2:45 PM-4:15 PM in the Moscone Center West Building (3001-3003-3014-3016).

“It’s very rewarding to see the clinical research being conducted by US Oncology Research affiliated community oncologists presented at this year’s 56th ASH annual meeting,” said Michael Seiden, M.D., Ph.D., Chief Medical Officer for McKesson Specialty Health and The US Oncology Network. “We believe that the leading clinicians working with US Oncology Research are helping to advance medical science and improve clinical outcomes by focusing on areas of significant unmet needs to bring meaningful innovation to patients in the communities they serve.”

In addition to the three oral presentations noted above, 17 other US Oncology Research affiliated trials will be featured as posters at this year’s meeting. A full list of US Oncology Research affiliated trials on display at the meeting is below. For more information or to interview a trial investigator, contact Dena Koklanaris, GCI Health on behalf of US Oncology Research, at 646-258-4659 or

Follow this link (PDF, 100 KB) to view a schedule of key data presentations from US Oncology Research.

About US Oncology Research

Supported by McKesson Specialty Health and The US Oncology Network, US Oncology Research draws from a network of experienced investigators and dedicated clinical staff who specialize in oncology clinical trials. US Oncology Research serves nearly 70 research sites and approximately 200 locations managing about 225 active trials at any given time. Physicians in the research network have enrolled nearly 60,000 patients in nearly 1,400 trials since inception in 1992 and have played a role in 50 FDA-approved cancer therapies, nearly one-third of all cancer therapies approved by the FDA to date. For more information call (800) 482-6700 or visit

About The US Oncology Network

The US Oncology Network is one of the nation's largest networks of integrated community-based oncology practices dedicated to advancing high-quality, evidence-based cancer care. A physician-led organization, The US Oncology Network unites like-minded physicians and clinicians around a common vision of improving patient outcomes and quality of life. Leveraging healthcare information technology, shared best practices, precise evidence-based guidelines and quality measurements, physicians within The US Oncology Network are pioneering new ways to achieve this vision. The US Oncology Network is committed to strengthening patient access to integrated care in local communities across the nation, including collaboration with a variety of regional payers, hospitals and academic institutions. The US Oncology Network is supported by McKesson Specialty Health, a division of McKesson Corporation focused on empowering a vibrant and sustainable community patient care delivery system. For more information, visit

About McKesson Specialty Health

McKesson Specialty Health, a division of McKesson Corporation, empowers the community patient care delivery system by helping community practices advance the science, technology and quality of care. Through innovative clinical, research, business and operational solutions, facilitated by integrated technology systems, we focus on improving the financial health of our customers so they may provide the best care to their patients. For more information, visit

Public Relations Contact